TY - JOUR
T1 - Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain
T2 - A monocentric retrospective study
AU - Ibba, Luciano
AU - Gargiulo, Luigi
AU - Bianco, Matteo
AU - Di Giulio, Sara
AU - Cascio Ingurgio, Ruggero
AU - Alfano, Angela
AU - Vignoli, Carlo A.
AU - Valenti, Mario
AU - Facheris, Paola
AU - Perugini, Chiara
AU - Narcisi, Alessandra
AU - Costanzo, Antonio
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site - for further information please contact [email protected].
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Janus kinase (JAK) inhibitors are widely used for treating atopic dermatitis (AD) and alopecia areata (AA). Weight gain is an emergent adverse event associated with JAK inhibitors, particularly those acting on the JAK2 pathway. We conducted a retrospective monocentric two-cohort study, including 226 patients, to evaluate the prevalence of weight gain in patients with AD and AA who were treated with JAK inhibitors for ≥ 1 year. We included 142 patients in the JAK1/2 cohort (receiving upadacitinib 30 mg or baricitinib 4 mg) and 84 in the JAK1 cohort (receiving upadacitinib 15 mg or abrocitinib 100 mg). The JAK1/2 cohort showed an additional weight gain throughout the study period (at week 52: β = 1.84, 95% confidence interval 1.41-2.28, P < 0.001). In conclusion, patients receiving JAK1/2 inhibitors for AD or AA are at a greater risk of weight gain than those treated with JAK1 inhibitors, likely because of impaired leptin signalling.
AB - Janus kinase (JAK) inhibitors are widely used for treating atopic dermatitis (AD) and alopecia areata (AA). Weight gain is an emergent adverse event associated with JAK inhibitors, particularly those acting on the JAK2 pathway. We conducted a retrospective monocentric two-cohort study, including 226 patients, to evaluate the prevalence of weight gain in patients with AD and AA who were treated with JAK inhibitors for ≥ 1 year. We included 142 patients in the JAK1/2 cohort (receiving upadacitinib 30 mg or baricitinib 4 mg) and 84 in the JAK1 cohort (receiving upadacitinib 15 mg or abrocitinib 100 mg). The JAK1/2 cohort showed an additional weight gain throughout the study period (at week 52: β = 1.84, 95% confidence interval 1.41-2.28, P < 0.001). In conclusion, patients receiving JAK1/2 inhibitors for AD or AA are at a greater risk of weight gain than those treated with JAK1 inhibitors, likely because of impaired leptin signalling.
UR - https://www.scopus.com/pages/publications/105013849232
U2 - 10.1093/ced/llaf144
DO - 10.1093/ced/llaf144
M3 - Article
C2 - 40172062
AN - SCOPUS:105013849232
SN - 0307-6938
VL - 50
SP - 1834
EP - 1837
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 9
ER -